2016 American Transplant Congress
Short, Cool and Well Oxygenated – HOPE for DCD Kidneys.
University Hospital, Zurich, Switzerland.
Background Organs from donors after cardiac death (DCD) suffer from severe loss of function requiring development of innovative methods of preservation. A novel perfusion approach,…2016 American Transplant Congress
Reduced-Dose Cidofovir (CID) and CMV-Hyperimmune Globulin (CMVIg) for Ganciclovir-Resistant Cytomegalovirus: Effective and Kidney Friendly.
Houston Methodist Hospital, Houston, TX.
Ganciclovir resistant (GR) CMV is associated with an aggressive disease course and substantial morbidity. Furthermore, treatment options such as foscarnet and cidofovir are incredibly nephrotoxic.…2016 American Transplant Congress
Ledipasvir/Sofosbuvir (LDV/SOF) for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients with Chronic Genotype 1 or 4 HCV Infection.
Background and Aims: Interferon (IFN) and ribavirin (RBV) for the treatment of chronic hepatitis C (HCV) in kidney transplant recipients is complicated by the risk…2015 American Transplant Congress
APOL1 High-Risk Genotype in African American Live Kidney Donors Is Not Associated With Post-Donation Development of Hypertension and Kidney Disease
African Americans (AA) with two apolipoprotein L1 (APOL1) risk alleles have more kidney disease than compared to those with one or zero risk alleles. A…2015 American Transplant Congress
Acute Kidney Injury in the Early Post Kidney Transplant Period: Frequency, Etiology and Significance
Acute kidney injury (AKI) post kidney transplant has not been well described using current diagnostic criteria. The frequency and etiology of AKI in the first…2015 American Transplant Congress
Quantifying Altruism in Kidney Donors: How Good Are the Current Scales?
The decision to become a living kidney donor is complicated and altruism is certainly what drives the majority of organ donors. Unfortunately, there are no…2015 American Transplant Congress
Cultural Domains Affecting Organ Donation in Indian Country
Background: The prevalence of end-stage renal disease is 3.5 times greater among the >2.5 million Native Americans or Alaskan Natives (NAs) in the US than…2015 American Transplant Congress
Living Donor Characteristics Associated With Changes in Post-Donation GFR
Living donor transplantation is the preferred modality for treatment of ESRD because it confers excellent outcomes for recipients and poses reasonable risks to most donors.…2015 American Transplant Congress
The Outcomes of Second Transplantation in Recurrent IgA Nephropathy
BackgroundRecurrence of original glomerulonephritis is an important cause of graft loss. In some studies, histologic recurrence of IgA nephropathy (IgAN) occurs in 60% after 1st…2015 American Transplant Congress
Ten-Year Follow-Up After Live Kidney Donation – A Prospective Cohort Study
BACKGROUNDPreviously reported short-term results after live kidney donation, show no negative consequences for the donor. The occurrence of e.g. cardiovascular diseases takes years to emerge,…
- « Previous Page
- 1
- …
- 93
- 94
- 95
- 96
- 97
- …
- 101
- Next Page »